Research progress on the clinical resistance to tigecycline

Abstract

Abstract: As a new glycylcycline antimicrobial agent, tigecycline (TIG) has been proved an effective therapeutic agent for the treatment of adult complicated intra-abdominal infections and complicated skin and skin structure infections. However, increasing evidence of drug resistance has been reported following the clinical treatment with TIG. This article offers an update overview of TIG pharmacological investigations, clinical applications, current microbial resistance and relative mechanisms.

Key words: tigecycline, drug resistance, resistance mechanism

CLC Number:

R978.1⁺4

LUO Dan, HAO Gang, LIN Si-si, GUO Wen-jing, XIA Yu-xuan, LV Liang-zhong. Research progress on the clinical resistance to tigecycline[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(4): 466-468.

References

[1] Brink AJ, Bizos D, Boffard KD, et al. Guideline: appropriate use of tigecycline[J]. S Afr Med J,2010,100 (6 Pt 2):388-394.
[2] Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: A comparative review with the tetracyclines[J]. Drugs,2004,64(1):63-88.
[3] Guay DR. Oritavancin and tigecycline: Investigational antimicrobials for multidrug-resistant bacteria[J]. Pharmacotherapy,2004,24(1):58-68.
[4] Giamarellou H, Poulakou G. Pharmacokinetic and pharmacodynamic evaluation of tigecycline[J]. Expert Opin Drug Metab Toxicol,2011,7(11):1459-1470.
[5] Bassetti M, Eckmann C, Bodmann KF, et al. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies[J]. J Antimicrob Chemother,2013,68:5-14.
[6] Sun Y, Cai Y, Liu X, et al. The emergence of clinical resistance to tigecycline[J]. Int J Antimicrob Agents,2013,41(2):110-116.
[7] Cai Y, Wang R, Liang B, et al. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease[J]. Antimicrob Agents Chemother,2011,55(3):1162-1172.
[8] Tasina E, Haidich AB, Kokkali S, et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: A meta-analysis[J]. Lancet Infect Dis,2011,11(11):834-844.
[9] Verkade EJ, Verhulst CJ, Huijsdens XW, et al. In vitro activity of tigecycline against methicillin-resistant staphylococcus aureus, including livestock-associated strains[J]. Eur J Clin Microbiol Infect Dis,2010,29(5):503-507.
[10]Garza-Gonzalez E, Llaca-Diaz JM, Bosques-Padilla FJ, et al. Prevalence of multidrug-resistant bacteria at a tertiary-care teaching hospital in mexico: Special focus on acinetobacter baumannii[J]. Chemotherapy,2010,56(4):275-279.
[11]Tubau F, Linares J, Rodriguez MD, et al. Susceptibility to tigecycline of isolates from samples collected in hospitalized patients with secondary peritonitis undergoing surgery[J]. Diagn Microbiol Infect Dis,2010,66(3):308-313.
[12]Darabi A, Hocquet D, Dowzicky MJ. Antimicrobial activity against streptococcus pneumoniae and haemophilus influenzae collected globally between,2004 and 2008 as part of the tigecycline evaluation and surveillance trial[J]. Diagn Microbiol Infect Dis,2010,67(1):78-86.
[13]李小宁, 李娟, 姚永红. 鲍曼不动杆菌的耐药性及产ESBL和碳青霉烯酶分析[J]. 中国临床药理学与治疗学, 2012, 17(1): 30-31.
[14]Chang KC, Lin MF, Lin NT, et al. Clonal spread of multidrug-resistant acinetobacter baumannii in eastern taiwan[J]. J Microbiol Immunol Infect,2012,45(1):37-42.
[15]Taneja N, Singh G, Singh M, et al. Emergence of tigecycline & colistin resistant acinetobacter baumanii in patients with complicated urinary tract infections in north india[J]. Indian J Med Res,2011,133:681-684.
[16]Al-Sweih NA, Al-Hubail MA, Rotimi VO. Emergence of tigecycline and colistin resistance in acinetobacter species isolated from patients in kuwait hospitals[J]. J Chemother,2011,23(1):13-16.
[17]Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant acinetobacter baumannii[J]. J Antimicrob Chemother,2007,59(1):772-774.
[18]Livermore DM, Warner M, Mushtaq S, et al. What remains against carbapenem-resistant enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline[J]. Int J Antimicrob Agents,2011,37(5):415-419.
[19]Zhang R, Sun Q, Hu YJ, et al. Detection of the smqnr quinolone protection gene and its prevalence in clinical isolates of stenotrophomonas maltophilia in china[J]. J Med Microbiol,2012,61(4):535-539.
[20]Linkevicius M, Sandegren L, Andersson DI. Mechanisms and fitness costs of tigecycline resistance in escherichia coli[J]. J Antimicrob Chemother,2013,68(12):2809-2019.[21]Keeney D, Ruzin A, McAleese F, et al. Mara-mediated overexpression of the acrab efflux pump results in decreased susceptibility to tigecycline in escherichia coli[J]. J Antimicrob Chemother,2008,61(1):46-53.
[22]Horiyama T, Nikaido E, Yamaguchi A, et al. Roles of salmonella multidrug efflux pumps in tigecycline resistance[J]. J Antimicrob Chemother,2011,66(1):105-110.
[23]Volkers G, Palm GJ, Weiss MS, et al. Structural basis for a new tetracycline resistance mechanism relying on the tetx monooxygenase[J]. FEBS Lett,2011,585(7):1061-1066.